MoST Companion Studies (C2)

These studies are collaborations between Omico and other groups or organisations that leverage the MoST screening program and complement the therapeutics program.

  • NHMRC Clinical Trials Centre | SHERLOCK: Sotorasib | KRAS G12C | Lung

    Title: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation.

    The aim of the SHERLOCK trial is to assess the activity and tolerability of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar in non-squamous metastatic NSCLC with KRAS G12C mutation.  

    Eligible Population: 

    KRAS G12C positive newly diagnosed, treatment naïve metastatic (Stage IV) non-squamous NSCLC or recurrent non-squamous NSCLC with no disease progression for at least 6 months following prior curative lung surgery and (neo)adjuvant chemotherapy, or prior curative concurrent chemoradiotherapy and immunotherapy maintenance, for non-resectable stage III cancer.

    Substudy status: Recruiting

    Registration number: ACTRN12622000973718

  • Olivia Newton-John Cancer Research Institute | MoST-CIRCUIT: Ipilimumab and Nivolumab | MSI-H | Pan tumour

    Title: Combination Immunotherapy in Rare Cancers Under InvesTigation: ipilimumab and nivolumab combination therapy in patients with selected immunotherapy sensitive advanced rare cancers

    The aim of this MoST companion study is to assess the clinical efficacy of of ipilimumab/nivolumab in rare cancer histotypes.

    Eligible Population: 

    Histologically confirmed:

    • Cohort 1: Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded).
    • Cohort 2: Biliary Tract Cancers: Intrahepatic cholangiocarcinoma, gallbladder carcinoma.
    • Cohort 3: Gynaecological malignancies: Ovarian clear cell carcinoma and uterine clear cell carcinoma.
    • Cohort 4: Mismatch repair protein deficient (MSI-H) cancers (excluding colorectal carcinoma).

    Substudy status: Recruiting

    Registration number: NCT04969887

  • Omico | MoST SPEAR - Sulfasalazine | No specific biomarker | Pancreas

    Title: A phase II, open-label, single-arm monotherapy trial of sulfasalazine in patients with pancreatic ductal adenocarcinoma

    The aim of this MoST companion study is to assess the clinical activity of sulfasalazine in MoST patients with pancreatic ductal adenocarcinoma.

    Eligible Population: 

    Patients with advanced pancreatic ductal adenocarcinoma and presence of tumour and/or stromal SLC7A11 expression who have progressive disease following prior treatment.

    Substudy status: Recruiting

    Registration number: ACTRN12621001347853

  • Omico | MoST-TAP | PD-L1, TMB, CD3, CD8, CD274 | Pan tumour

    Title: A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours

    The aim of this study is to evaluate the effect of 2 monoclonal antibodies, tiragolumab and atezolizumab, in patients with locally advanced solid cancers which cannot be removed by surgery or have spread.

    Eligible Population: 

    • Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumour. Non-small cell lung cancer excluded
    • Exhausted all available standard therapy or not suitable for standard therapy (including targeted therapies) for the tumour
    • Sufficient and accessible tumour tissue for panel sequencing, PD-L1 and TIL testing, and tertiary objectives
    • Tumour biomarker criteria predictive of immune response defined by presence of one or more of the following: 
      • tumour mutation burden ≥ 10 mutations per megabase
      • tumour PD-L1 expression TAP score ≥ 5%
      • PD-L1 amplification >6 copy number alterations
      • tumour infiltrating lymphocytes (TILs) (CD3+CD8+) ≥ 5%

    Substudy status: Recruiting

    Registration number: NCT06003621

Our Network

A national network of sites recruiting patients into our programs

Interested in knowing more?

Get in touch